These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 32215778)
1. Changes of focal macular and full-field electroretinograms after intravitreal aflibercept in patients with central retinal vein occlusion. Nishimura T; Machida S; Hara Y Doc Ophthalmol; 2020 Oct; 141(2):169-179. PubMed ID: 32215778 [TBL] [Abstract][Full Text] [Related]
2. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results. Nishimura T; Machida S; Tada A; Oshida E; Muto T Doc Ophthalmol; 2020 Oct; 141(2):127-136. PubMed ID: 32100140 [TBL] [Abstract][Full Text] [Related]
3. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion. Nishimura T; Machida S; Tada A; Oshida E; Muto T Doc Ophthalmol; 2019 Aug; 139(1):67-74. PubMed ID: 30980231 [TBL] [Abstract][Full Text] [Related]
4. Changes in cone-driven functions after intravitreal aflibercept injections in patients with age-related macular degeneration. Nishimura T; Machida S; Hara Y Doc Ophthalmol; 2020 Oct; 141(2):137-147. PubMed ID: 32100141 [TBL] [Abstract][Full Text] [Related]
5. Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion. Gardašević Topčić I; Šuštar M; Brecelj J; Hawlina M; Jaki Mekjavić P Doc Ophthalmol; 2014 Aug; 129(1):27-38. PubMed ID: 24906869 [TBL] [Abstract][Full Text] [Related]
6. A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion - an 18-month prospective cohort study. O'Day R; Ali N; Lim LL; Sandhu S; Chau T; Wickremasinghe S BMC Ophthalmol; 2020 Feb; 20(1):69. PubMed ID: 32093666 [TBL] [Abstract][Full Text] [Related]
7. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion. Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163 [TBL] [Abstract][Full Text] [Related]
8. EVALUATION OF SHORT-TERM OUTCOMES OF INTRAVITREAL AFLIBERCEPT INJECTIONS FOR AGE-RELATED MACULAR DEGENERATION USING FOCAL MACULAR ELECTRORETINOGRAPHY. Takayama K; Kaneko H; Ueno S; Maruko R; Piao CH; Yasuda S; Kawano K; Ito Y; Terasaki H Retina; 2017 Mar; 37(3):553-560. PubMed ID: 27465570 [TBL] [Abstract][Full Text] [Related]
9. SCORE2 Report 2: Study Design and Baseline Characteristics. Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Figueroa M; Dugel PU; Ophthalmology; 2017 Feb; 124(2):245-256. PubMed ID: 27863843 [TBL] [Abstract][Full Text] [Related]
10. Flicker electroretinograms before and after intravitreal ranibizumab injection in eyes with central retinal vein occlusion. Yasuda S; Kachi S; Ueno S; Piao CH; Terasaki H Acta Ophthalmol; 2015 Sep; 93(6):e465-8. PubMed ID: 25597703 [TBL] [Abstract][Full Text] [Related]
11. Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion. Loukianou E; Brouzas D; Chatzistefanou K; Koutsandrea C Int Ophthalmol; 2016 Feb; 36(1):21-36. PubMed ID: 25820576 [TBL] [Abstract][Full Text] [Related]
12. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial. Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA; Chan CK; JAMA Ophthalmol; 2019 Dec; 137(12):1389-1398. PubMed ID: 31600368 [TBL] [Abstract][Full Text] [Related]
13. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Lotfy A; Solaiman KAM; Abdelrahman A; Samir A Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699 [TBL] [Abstract][Full Text] [Related]
15. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion. Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324 [TBL] [Abstract][Full Text] [Related]
16. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion. Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794 [TBL] [Abstract][Full Text] [Related]
18. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. Pichi F; Elbarky AM; Elhamaky TR Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022 [TBL] [Abstract][Full Text] [Related]
19. EVALUATION OF MACULAR ISCHEMIA IN EYES WITH CENTRAL RETINAL VEIN OCCLUSION: An Optical Coherence Tomography Angiography Study. Ghashut R; Muraoka Y; Ooto S; Iida Y; Miwa Y; Suzuma K; Murakami T; Kadomoto S; Tsujikawa A; Yoshimura N Retina; 2018 Aug; 38(8):1571-1580. PubMed ID: 28671896 [TBL] [Abstract][Full Text] [Related]
20. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Korobelnik JF; Holz FG; Roider J; Ogura Y; Simader C; Schmidt-Erfurth U; Lorenz K; Honda M; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R; Ophthalmology; 2014 Jan; 121(1):202-208. PubMed ID: 24084497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]